- Bio-Techne’s 4th quarter adjusted earnings per share (EPS) were 53 cents, surpassing estimates of 50 cents and last year’s figures of 49 cents.
- Net sales reached $317.0 million, showing a 3.5% year-over-year increase and exceeding the estimate of $314.6 million.
- Protein Sciences led the growth with net sales of $226.5 million, marking a 5.8% year-over-year rise and surpassing the $221.8 million estimate.
- In contrast, Diagnostics & Genomics saw a slight decrease in net sales to $89.7 million, down 1.1% from the previous year and below the estimate of $92.4 million.
- The adjusted gross margin stood at 70%, slightly below last year’s 71.1% and aligned with the estimate of 70.2%.
- The adjusted operating margin was 32%, falling from last year’s 33.5% but close to the estimate of 32.3%.
- CEO Kim Kelderman noted the company delivered a solid fourth quarter performance, particularly in cell therapy and protein analysis, despite market uncertainties.
- Bio-Techne’s stock ratings from analysts include 13 buy recommendations, 6 holds, and no sell ratings.
Bio Techne Corp on Smartkarma
Analysts on Smartkarma, like those at Baptista Research, are closely monitoring Bio-Techne Corp. Recent reports provide valuable insights into the company’s performance and market dynamics. In a report focusing on the third quarter of fiscal year 2025, Bio-Techne displayed resilience in a challenging economic environment. With a 6% organic revenue growth and a strong 34.9% adjusted operating margin, the company showcased the importance of its diversified product portfolio, including core reagents, analytical solutions, and gene therapy offerings.
Furthermore, in another report by Baptista Research, the spotlight was on Bio-Techne’s second quarter of fiscal year 2025. The company reported a 9% year-over-year revenue increase, reaching $297 million in sales. This growth was driven by strong performances in biopharma markets and advancements in areas like Good Manufacturing Practice (GMP) reagents and spatial biology divisions. The analysts’ sentiment on Bio-Techne Corp remains bullish, emphasizing the company’s growth potential and strategic developments in key market segments.
A look at Bio Techne Corp Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Bio Techne Corp shows a balanced long-term outlook across various key factors. The company scores moderately on Value, Growth, Resilience, and Momentum, indicating a stable and promising future. Bio Techne Corp‘s diversified portfolio of biotechnology products and clinical diagnostic controls positions it well to capitalize on industry trends and opportunities for sustained growth.
With a solid score in Resilience, Bio Techne Corp demonstrates the ability to weather market fluctuations and challenges. Combined with decent scores in Value and Growth, the company showcases potential for value creation and expansion in the long run. Furthermore, its emphasis on proteins, cytokines, growth factors, immunoassays, and small molecules underscores a commitment to innovation and advancement in the biotechnology sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
